Click on these pictures to learn more about Curemark's pipeline.
News
Orlando Business Journal: Local Med Office Named Clinical Trial Site
Friday, October 16th - 2009
Curemark LLC, a drug research and development company, has enrolled the first patients in Phase III clinical trials for its autism treatment, CM-AT, including patients at Lake Mary Pediatrics in Orange City.
The west Volusia County physicians’ office is one of 12 clinical trial sites with a total 170 children across the country, according to a Curemark release.
CM-AT is based on research by Curemark founder and CEO Dr. Joan Fallon that showed enzyme deficiencies in autistic children, resulting in an inability to digest protein. The inability to digest protein affects the production of amino acids, the building blocks of chemicals essential for brain function.
"We’re hopeful that CM-AT will be one of the first therapies to address the underlying physiology of autism, rather than just treat its symptoms,” said Fallon.
A new study released in early October by the U.S. Centers for Disease Control reported that autism affects one in 91 children and about one in 58 boys — an estimated 673,000, or approximately 1 percent of all children in the U.S. Curemark is a New York-based drug research and development company focused on the treatment of neurological and other diseases by addressing certain key gastrointestinal/pancreatic secretory deficiencies.
http://orlando.bizjournals.com/orlando/stories/2009/10/12/daily51.html
